Q2 STOCKS TO BUY

Pharma Stock Falls Amid Workforce Reduction Plans

The stock hit a 13-year low last month

Deputy Editor
Jan 9, 2023 at 10:30 AM
facebook X logo linkedin


Emergent BioSolutions Inc (NYSE:EBS) is in the news today, after the pharmaceutical company announced it was cutting its workforce by roughly 5%. The move, along with other cost reduction measures, will save over $60 million in annual expenses. 

EBS has reversed its premarket gains, however, and was down 5.2% at $12.87 at last glance. The security sports a 73.2% year-over-year deficit, but had been moving steadily higher since its Dec. 22, 13-year low of $10.61. A short-term drop could be in the cards, however, as the stock's 14-day relative strength index (RSI) of 84.5 sits in "overbought" territory. 

Of the five analysts in coverage, four sport a "hold" rating, with one a "strong buy." Meanwhile, short interest has been on the rise, and represents 7.7% of the stock's available float, or nearly four days' worth of pent-up buying power. 

 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here